• Je něco špatně v tomto záznamu ?

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial

HC. Kluin-Nelemans, E. Hoster, O. Hermine, J. Walewski, CH. Geisler, M. Trneny, S. Stilgenbauer, F. Kaiser, JK. Doorduijn, G. Salles, M. Szymczyk, H. Tilly, L. Kanz, C. Schmidt, P. Feugier, C. Thieblemont, JM. Zijlstra, V. Ribrag, W. Klapper, C....

. 2020 ; 38 (3) : 248-256. [pub] 20191205

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025262

PURPOSE: In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy and safety of long-term use of rituximab maintenance. PATIENTS AND METHODS: Five hundred sixty patients with newly diagnosed MCL underwent a first random assignment between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, fludarabine, and cyclophosphamide (R-FC) induction, followed by a second random assignment in 316 responders between rituximab and interferon alfa maintenance, to be continued until progression. We compared progression-free survival from the second randomization and overall survival (OS) from the first or second randomizations. RESULTS: After a median follow-up time of 7.6 years, the previously described difference in OS between the induction arms persisted (median, 6.4 years after R-CHOP [n = 280] v 3.9 years after R-FC [n = 280]; P = .0054). Patients responding to R-CHOP had median progression-free survival and OS times of 5.4 and 9.8 years, respectively, when randomly assigned to rituximab (n = 87), compared with 1.9 years (P < .001) and 7.1 years (P = .0026), respectively, when randomly assigned to interferon alfa (n = 97). In 58% and 32% of patients treated with R-CHOP, rituximab maintenance was still ongoing 2 and 5 years from start of maintenance, respectively. After R-FC, rituximab maintenance was associated with an unexpectedly high cumulative incidence of death in remission (22% at 5 years). Toxicity of rituximab maintenance was low after R-CHOP (grade 3-4 leukopenia or infection < 5%) but more prominent in patients on rituximab maintenance after R-FC, in whom grade 3-4 leukopenia (up to 40%) and infections were frequent (up to 15%). CONCLUSION: The excellent results of R-CHOP followed by rituximab maintenance until progression for older patients with MCL persisted in a mature follow-up. Prolongation of rituximab maintenance beyond 2 years is effective and safe.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025262
003      
CZ-PrNML
005      
20201222155133.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.19.01294 $2 doi
035    __
$a (PubMed)31804876
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kluin-Nelemans, Hanneke C $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
245    10
$a Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial / $c HC. Kluin-Nelemans, E. Hoster, O. Hermine, J. Walewski, CH. Geisler, M. Trneny, S. Stilgenbauer, F. Kaiser, JK. Doorduijn, G. Salles, M. Szymczyk, H. Tilly, L. Kanz, C. Schmidt, P. Feugier, C. Thieblemont, JM. Zijlstra, V. Ribrag, W. Klapper, C. Pott, M. Unterhalt, MH. Dreyling,
520    9_
$a PURPOSE: In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy and safety of long-term use of rituximab maintenance. PATIENTS AND METHODS: Five hundred sixty patients with newly diagnosed MCL underwent a first random assignment between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, fludarabine, and cyclophosphamide (R-FC) induction, followed by a second random assignment in 316 responders between rituximab and interferon alfa maintenance, to be continued until progression. We compared progression-free survival from the second randomization and overall survival (OS) from the first or second randomizations. RESULTS: After a median follow-up time of 7.6 years, the previously described difference in OS between the induction arms persisted (median, 6.4 years after R-CHOP [n = 280] v 3.9 years after R-FC [n = 280]; P = .0054). Patients responding to R-CHOP had median progression-free survival and OS times of 5.4 and 9.8 years, respectively, when randomly assigned to rituximab (n = 87), compared with 1.9 years (P < .001) and 7.1 years (P = .0026), respectively, when randomly assigned to interferon alfa (n = 97). In 58% and 32% of patients treated with R-CHOP, rituximab maintenance was still ongoing 2 and 5 years from start of maintenance, respectively. After R-FC, rituximab maintenance was associated with an unexpectedly high cumulative incidence of death in remission (22% at 5 years). Toxicity of rituximab maintenance was low after R-CHOP (grade 3-4 leukopenia or infection < 5%) but more prominent in patients on rituximab maintenance after R-FC, in whom grade 3-4 leukopenia (up to 40%) and infections were frequent (up to 15%). CONCLUSION: The excellent results of R-CHOP followed by rituximab maintenance until progression for older patients with MCL persisted in a mature follow-up. Prolongation of rituximab maintenance beyond 2 years is effective and safe.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a indukční chemoterapie $x metody $7 D060828
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $7 D020522
650    _2
$a udržovací chemoterapie $x metody $7 D060046
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a čas $7 D013995
650    _2
$a vidarabin $x aplikace a dávkování $x analogy a deriváty $7 D014740
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hoster, Eva $u University Hospital Ludwig-Maximilians-University Munich, Munich, Germany.
700    1_
$a Hermine, Olivier $u Hôpital Necker, Institut Imagine, Assistance Publique-Hôpitaux de Paris, University Paris Descartes, Paris, France.
700    1_
$a Walewski, Jan $u Maria Sklodowska-Curie Institute, Warsaw, Poland.
700    1_
$a Geisler, Christian H $u Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Trneny, Marek $u Charles University General Hospital, Prague, Czech Republic.
700    1_
$a Stilgenbauer, Stephan $u University of Ulm, Ulm, Germany.
700    1_
$a Kaiser, Florian $u VK&K Studien GbR, Landshut, Germany.
700    1_
$a Doorduijn, Jeanette K $u Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
700    1_
$a Salles, Gilles $u Hospices Civils de Lyon, University of Lyon, Pierre-Benite, France.
700    1_
$a Szymczyk, Michal $u Maria Sklodowska-Curie Institute, Warsaw, Poland.
700    1_
$a Tilly, Hervé $u Centre Henri Becquerel, Rouen, France.
700    1_
$a Kanz, Lothar $u University of Tübingen, Tübingen, Germany.
700    1_
$a Schmidt, Christian $u University Hospital Ludwig-Maximilians-University Munich, Munich, Germany.
700    1_
$a Feugier, Pierre $u Center Hospitalier Regional and University Nancy Vandoeuvre les Nancy, Nancy, France.
700    1_
$a Thieblemont, Catherine $u Hôpital Saint Louis, Paris, France.
700    1_
$a Zijlstra, Josée M $u Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
700    1_
$a Ribrag, Vincent $u Institut Gustave Roussy, Villejuif, France.
700    1_
$a Klapper, Wolfram $u University of Kiel, Kiel, Germany.
700    1_
$a Pott, Christiane $u University Hospital Schleswig-Holstein Campus Kiel/Christian-Albrechts University Kiel, Kiel, Germany.
700    1_
$a Unterhalt, Michael $u University Hospital Ludwig-Maximilians-University Munich, Munich, Germany.
700    1_
$a Dreyling, Martin H $u University Hospital Ludwig-Maximilians-University Munich, Munich, Germany.
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 38, č. 3 (2020), s. 248-256
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31804876 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155129 $b ABA008
999    __
$a ok $b bmc $g 1599407 $s 1115948
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 3 $d 248-256 $e 20191205 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace